3.3 Anti-obesity medicine Anti-obesity medicine (AOM) options that are currently approved by the US Food and Drug Administration (FDA) include liraglutide, phentermine, phentermine/topiramate extended release (ER), naltrexone sustained release (SR) /bupropion sustained release (SR) and orlistat (52)
Let's be honest: starting Ozempic, Wegovy, or Zepbound can feel like signing up for a digestive rollercoaster
However, comprehensive data on the direct effects of HF are still being developed (NCT04847557)
The formula is safe, effective, and optimized for both
it cannot establish superiority, because differences in population, comparator, endpoint, dose, and trial length confound any direct read
Valerie Agyeman, R.D.N., a registered dietitian and spokesperson for Benefiber